A 6 Month Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol in The Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older

NCT01067105 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

824

Enrollment

INDUSTRY

Sponsor class

Conditions

Perennial Allergic Rhinitis

Interventions

DRUG: ciclesonide HFA 160 μg

Sponsor

Sumitomo Pharma America, Inc.